Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PB016 vs Entyvio in Ulcerative Colitis
NCT05771155Phase 3Active, not recruiting
- Sponsor
- Polpharma Biologics
- Start
- Jul 2023
- Primary completion
- Sep 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of vedolizumab in ulcerative colitis (UC) (2 arms), sponsored by Polpharma Biologics. Primary endpoint: Clinical Response Rate at 6 weeks. Started Jul 2023; status: active, not recruiting.
02
Drugs
vedolizumab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT05771155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05771155.